Our results reported different pCR rates in the various tumor subtypes (52.3% in HER2+/HR+, 74.2% in HER2+/HR-negative, 17.2% in HER2-negative/HR+ and 37.9% in triple negative breast cancer), but these percentages resulted similar to or higher, for each subgroup, than what is reported in the literature [11,16]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.